Clinical Trial Update: iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing iGlarLixi to IDegAsp in Chinese adults with Type 2 Diabetes Mellitus who are inadequately controlled on oral antidiabetic drugs; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• IDegAsp (insulin degludec/insulin aspart)
• iGlarLixi (insulin glargine + lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2024-10-30